Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort

Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort

Abstract Glioblastoma is immunologically “cold” and resistant to single-agent immune-checkpoint inhibitors (ICI). Our previous study of neoadjuvant pembrolizumab in surgically-accessible recurrent glioblastoma identified a molecular signature of response to ICI and suggested that neoadjuvant pembrol...

Full description

Saved in:
Bibliographic Details
Main Authors: J. Ricardo McFaline-Figueroa, Lu Sun, Gilbert C. Youssef, Raymond Huang, Gang Li, Jiyoon Kim, Eudocia Q. Lee, Lakshmi Nayak, Ugonma Chukwueke, Rameen Beroukhim, Tracy T. Batchelor, E. Antonio Chiocca, Richard G. Everson, Lisa Doherty, Jennifer Stefanik, Kathryn Partridge, Amanda Spearman, Alexa Myers, Catharina Westergaard, Alyssa Russ, Maria Lavallee, Anna Smokovich, Corey LaForest-Roys, Rachel Garcia Fox, Christine McCluskey, Wenya Linda Bi, Omar Arnaout, PierPaolo Peruzzi, G. Rees Cosgrove, Keith L. Ligon, Isabel Arrillaga-Romany, Jennifer L. Clarke, David A. Reardon, Timothy F. Cloughesy, Robert M. Prins, Patrick Y. Wen
Format: Article
Language:English
Published: Nature Portfolio 2024-12-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-024-54326-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41467-024-54326-7

Similar Items